Aim
To compare the costs and consequences of providing test results by near patient testing (NPT) compared with conventional testing. The effect of the testing method on the process of care, the accuracy of testing, patient satisfaction, clinical attitudes, and health service and patient costs was investigated. A secondary aim was to generate hypotheses concerning the effect of the testing method on clinical outcome.
Methods and results
Three alternative strategies for analysing and providing test information for patients attending routine diabetes clinics at the Guy's & St Thomas's Hospitals NHS Trust were considered.
1. Conventional testing: when a patient attended the clinic the doctor had the option of requesting a test. Results were then sent for processing at a central laboratory with a delay of 5-7 days before requested results were returned. An NPT service for the measurement of glycosylated haemoglobin (HbA 1C ) 
Process of care
A controlled trial compared the effect of the testing method on the process of care. A total of 599 patients were alternately allocated to either nurse NPT or conventional testing. The number of management changes to the patients' diet, insulin or tablet therapy was recorded for all the patients.
The results showed that patients were more likely to have a change in management related to their glycaemic control if they had been in the NPT rather than the conventional testing group (odds ratio 1.52; 95% confidence interval (CI) There did not seem to be any improvement in the process of care from providing lipid or creatinine results immediately, which suggests that the merits of NPT are likely to vary according to the test in question.
Accuracy of test results
NPT in general maintained acceptable standards of quality control.
Patient satisfaction and patient knowledge
Self-administered patient questionnaires were used to assess levels of patient satisfaction with the alternative strategies. Patients for both NPT strategies were significantly more satisfied with the test information provided, than those who were conventionally tested (laboratory NPT versus conventional, p = 0.004; nurse NPT versus conventional, p < 0.001).
A higher proportion of users of the NPT services recalled being told the result of their HbA 1C test (64%) compared with those who used the conventional testing service (19%). For a minority of patients in the conventional group, HbA 1C results were provided immediately.
Clinical attitudes
A sample of doctors interviewed stated that immediate access to HbA 1C results meant that they could make more informed decisions about what changes in management should be implemented.
Executive summary
They also said that without immediate access to test results, changes in patient management might be sub-optimal.
Conventional testing was considered adequate for lipids and creatinine results. Some clinicians were concerned that NPT may lead to organisational delays in the diabetes clinic.
Clinical outcome
A retrospective cohort study compared intermediate clinical outcome, measured by mean HbA 1C , between patients using conventional (n = 500) and laboratory NPT (n = 500) strategies. This aspect of the study aimed to generate further hypotheses concerning the effect of testing method on clinical outcome. After controlling for case-mix variables, mean HbA 1C was significantly lower for the NPT cohort compared with the conventional testing cohort. The potential for confounding in the design of the study means that a prospective randomised controlled trial (RCT) is required to investigate further the effects of NPT on patient outcome.
Health service costs
The number of tests and the use of staff time was measured for a sample of patients tested by each method. The costs of conventional testing were then compared with both NPT strategies. Mean visit costs were £3.80 higher for laboratory NPT and £12.60 higher for nurse NPT than for conventional testing, reflecting the greater number of tests conducted at NPT visits and the higher capital equipment costs of NPT. However, sensitivity analysis showed that the additional costs fell if NPT was used just for HbA 1C tests. In this study, the mean difference in annual costs between the two approaches was not significant as the mean number of visits per year was lower for laboratory NPT.
Patient costs
Patient questionnaires were used to measure the patient costs associated with each method. Patient time per visit did not vary according to the testing method used. Users of the laboratory NPT service made fewer visits to the diabetes clinic (1.81 per annum) compared with users of the conventional testing clinic (2.28 per annum). This meant that in the settings examined, annual patient costs were higher for conventional testing than for NPT.
Frequency of patient visits
Health service and patient costs are affected by the impact of NPT on the frequency of patient visits to clinics. In this study, users of an established NPT service made fewer hospital visits per annum than those of a conventional service. However, it is not possible to say that these differences were a direct result of NPT or due to other differences in clinical practices and the organisation of care between the two hospital sites.
Other results from this study support a hypothesis that there may be a direct link between NPT and the frequency with which patients need to attend hospital clinics. Generally, under conventional testing, results which were not immediately available were not mailed to either the patient or their general practitioner. The users of the test information were thus hospital doctors and the next available time that the information could be used to support a management change was during the patient's next hospital appointment. This method of transmitting and using test information may mean that under conventional care patients need to be called to the clinic more frequently.
A prospective RCT is needed to firmly establish the link between NPT and the frequency of patient visits to clinics.
Future research
The results of this initial research project indicate that providing HbA 1C results by NPT seems to improve the process of care and aspects of patient satisfaction. A prospective RCT of NPT in diabetes clinics is now needed. The aims of this trial should be to establish:
• the impact of NPT on clinical outcomes • the impact of NPT on the frequency of patient visits to clinics • the impact of any changes in the above on health service and patient costs.
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